RS57390B1 - Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja - Google Patents

Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja

Info

Publication number
RS57390B1
RS57390B1 RS20180807A RSP20180807A RS57390B1 RS 57390 B1 RS57390 B1 RS 57390B1 RS 20180807 A RS20180807 A RS 20180807A RS P20180807 A RSP20180807 A RS P20180807A RS 57390 B1 RS57390 B1 RS 57390B1
Authority
RS
Serbia
Prior art keywords
pharmaceutically acceptable
optionally substituted
compound according
alkyl
certain embodiments
Prior art date
Application number
RS20180807A
Other languages
English (en)
Serbian (sr)
Inventor
Douglas Covey
Albert Jean Robichaud
Original Assignee
Univ Washington
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Sage Therapeutics Inc filed Critical Univ Washington
Publication of RS57390B1 publication Critical patent/RS57390B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0029—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
RS20180807A 2012-12-18 2013-12-18 Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja RS57390B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261738822P 2012-12-18 2012-12-18
EP13865411.6A EP2935307B1 (en) 2012-12-18 2013-12-18 Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment
PCT/US2013/076214 WO2014100228A1 (en) 2012-12-18 2013-12-18 Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same

Publications (1)

Publication Number Publication Date
RS57390B1 true RS57390B1 (sr) 2018-09-28

Family

ID=50979162

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180807A RS57390B1 (sr) 2012-12-18 2013-12-18 Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja

Country Status (27)

Country Link
US (7) US9630986B2 (OSRAM)
EP (3) EP3392260B1 (OSRAM)
JP (5) JP6542127B2 (OSRAM)
KR (3) KR102400891B1 (OSRAM)
CN (3) CN114605486A (OSRAM)
AU (5) AU2013361485B2 (OSRAM)
BR (1) BR112015014397B1 (OSRAM)
CA (1) CA2895513C (OSRAM)
CY (1) CY1121150T1 (OSRAM)
DK (1) DK2935307T3 (OSRAM)
ES (2) ES2933987T3 (OSRAM)
HR (1) HRP20181048T1 (OSRAM)
HU (1) HUE039057T2 (OSRAM)
IL (3) IL278396B2 (OSRAM)
LT (1) LT2935307T (OSRAM)
MX (2) MX365644B (OSRAM)
NZ (2) NZ709211A (OSRAM)
PH (2) PH12018502141A1 (OSRAM)
PL (1) PL2935307T3 (OSRAM)
PT (2) PT3392260T (OSRAM)
RS (1) RS57390B1 (OSRAM)
RU (1) RU2663665C2 (OSRAM)
SG (3) SG10201706063UA (OSRAM)
SI (2) SI3392260T1 (OSRAM)
SM (1) SMT201800422T1 (OSRAM)
TR (1) TR201808616T4 (OSRAM)
WO (1) WO2014100228A1 (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1959966B1 (en) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolone formulations and methods for the making and use thereof
AU2012304412A1 (en) 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT2766380T (pt) 2011-10-14 2019-07-29 Sage Therapeutics Inc Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos
RS59734B1 (sr) 2012-01-23 2020-02-28 Sage Therapeutics Inc Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina
EP2887944B1 (en) 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
KR102400891B1 (ko) 2012-12-18 2022-05-20 워싱톤 유니버시티 신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
KR102614507B1 (ko) 2013-04-17 2023-12-19 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
PL2986624T3 (pl) 2013-04-17 2020-11-16 Sage Therapeutics, Inc. Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
CA3199003A1 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
HUE052308T2 (hu) 2013-08-23 2021-04-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásuk
WO2015195967A1 (en) * 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP3206493B1 (en) 2014-10-16 2020-05-06 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN117024502A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
ES2857082T3 (es) 2015-01-26 2021-09-28 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
JP6875996B2 (ja) * 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
CN113292623A (zh) 2015-07-06 2021-08-24 萨奇治疗股份有限公司 孕甾醇及其使用方法
EP3319610A4 (en) 2015-07-06 2019-03-06 Sage Therapeutics, Inc. OXYSTEROLS AND METHOD OF USE THEREOF
PT3319612T (pt) 2015-07-06 2021-08-24 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
EA036155B1 (ru) 2015-10-16 2020-10-06 Маринус Фармасьютикалс, Инк. Инъекционные составы нейростероида, содержащие наночастицы
WO2017087864A1 (en) * 2015-11-20 2017-05-26 Sage Therapeutics, Inc. Compounds and methods of their use
AU2017229656B2 (en) 2016-03-08 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
KR20230079470A (ko) 2016-08-23 2023-06-07 세이지 테라퓨틱스, 인크. 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
ES2935057T3 (es) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
BR112019008032A2 (pt) 2016-10-18 2019-09-03 Sage Therapeutics, Inc. oxiesteróis e métodos de uso dos mesmos
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
CN109988210B (zh) * 2017-12-30 2022-05-17 天津药业研究院股份有限公司 一种黄体酮和黄体酮中间体的制备方法
JP7671244B2 (ja) 2018-10-12 2025-05-01 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド
CN109289095B (zh) * 2018-11-23 2021-03-26 淮海工学院 一种含盐酸利多卡因的肠镜凝胶剂及其制备方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020243488A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
EP4125921A1 (en) 2020-03-25 2023-02-08 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
CN117801047B (zh) * 2023-01-19 2024-12-20 北京华睿鼎信科技有限公司 神经甾体衍生物及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB820779A (en) * 1954-12-08 1959-09-23 Syntex Sa Cyclopentanophenanthrene derivatives
US2856415A (en) * 1957-11-13 1958-10-14 Searle & Co 3,19-dihydroxy-5-androstene derivatives
NL292848A (OSRAM) * 1962-05-16
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US4239681A (en) * 1974-04-15 1980-12-16 Richardson-Merrell Inc. Androst-4-en-19-ols
US4022769A (en) * 1974-05-13 1977-05-10 Richardson-Merrell Inc. Androst-4-en-19-ones
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4071625A (en) * 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
DE2632677A1 (de) 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
MA18433A1 (fr) * 1978-05-26 1979-12-31 Ciba Geigy Ag Procede pour la synthese de la chaine laterale hydroxyacetyle de steroides du type pregnagne, nouveaux 21-hydroxy-20-oxo-17 alpha-pregnagnes et produits pharmaceutiques en renfermant
US4389345A (en) 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) 1982-09-03 1985-01-22 G. D. Searle & Co. Aminoalkyl steroids
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
US5661141A (en) * 1995-03-27 1997-08-26 Petrow; Vladimir 19-oxygenated steroids as therapeutic agents
PL185523B1 (pl) 1995-06-06 2003-05-30 Cocensys Inc Neuroaktywne steroidy z grupy pochodnych androstanu i pregnanu oraz kompozycja farmaceutyczna
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6855836B2 (en) 2000-10-26 2005-02-15 Jenapharm Gmbh & Co. Kg 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
US6844456B2 (en) 2000-11-03 2005-01-18 Washington University Modified, hydroxy-substituted aromatic structures having cytoprotective activity
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
DK1608671T3 (da) 2003-03-24 2010-05-10 Sterix Ltd Østrogenderivater som inhibitorer af steroidsulfatase
CN1281561C (zh) * 2003-04-23 2006-10-25 中国科学院上海有机化学研究所 一种具有1，6－亚甲基－[10]－轮烯基本骨架的化合物及其用途
WO2005000869A1 (en) * 2003-05-29 2005-01-06 Washington University Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
AU2004292555A1 (en) * 2003-11-24 2005-06-09 Merck & Co., Inc. Estrogen receptor modulators
CN100376685C (zh) * 2005-01-14 2008-03-26 天津科技大学 微生物转化法制备雌酚酮的方法
EP1868593A2 (en) * 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
US8575375B2 (en) * 2007-06-15 2013-11-05 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
WO2012013816A1 (en) 2010-07-30 2012-02-02 Medexis S.A. Compounds and methods for treating neoplasia
CN103347525A (zh) 2010-12-15 2013-10-09 哈博生物科学公司 制备3α-氧取代的甾族化合物的方法及化合物
WO2012116290A2 (en) 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP2987866B1 (en) 2011-03-23 2017-12-06 Etsuro Ito Method and kit for super-high-sensitivity measurement of protein and nucleic acid, and novel enzyme substrate
WO2013188792A2 (en) * 2012-06-15 2013-12-19 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2014058736A1 (en) * 2012-10-08 2014-04-17 Washington University Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
KR102400891B1 (ko) 2012-12-18 2022-05-20 워싱톤 유니버시티 신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
HUE052308T2 (hu) 2013-08-23 2021-04-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásuk

Also Published As

Publication number Publication date
PH12015501404B1 (en) 2020-09-18
JP7241792B2 (ja) 2023-03-17
SMT201800422T1 (it) 2018-09-13
IL239501A0 (en) 2015-08-31
IL239501B (en) 2020-11-30
EP4086270A1 (en) 2022-11-09
ES2933987T3 (es) 2023-02-15
AU2013361485A1 (en) 2015-07-09
KR102265408B1 (ko) 2021-06-16
MX365644B (es) 2019-06-10
US20210308149A1 (en) 2021-10-07
MX2019006739A (es) 2019-08-22
US9630986B2 (en) 2017-04-25
DK2935307T3 (en) 2018-07-30
AU2013361485B2 (en) 2018-05-17
PT3392260T (pt) 2022-12-27
PL2935307T3 (pl) 2018-09-28
TR201808616T4 (tr) 2018-07-23
SI3392260T1 (sl) 2023-01-31
SG10201809638YA (en) 2018-11-29
CN105026415B (zh) 2019-02-01
RU2015129546A (ru) 2017-01-24
NZ739760A (en) 2020-05-29
US20140235600A1 (en) 2014-08-21
MX2015007900A (es) 2016-02-05
PH12015501404A1 (en) 2015-09-07
SI2935307T1 (en) 2018-08-31
HRP20181048T1 (hr) 2018-08-24
KR20210072151A (ko) 2021-06-16
BR112015014397B1 (pt) 2021-02-02
US20170232006A1 (en) 2017-08-17
IL310501A (en) 2024-03-01
HUE039057T2 (hu) 2018-12-28
JP2023071910A (ja) 2023-05-23
AU2021290223B2 (en) 2024-01-18
LT2935307T (lt) 2018-07-25
AU2021290223A1 (en) 2022-01-20
MX388946B (es) 2025-03-20
AU2018217213B2 (en) 2020-03-12
AU2024202233A1 (en) 2024-05-02
US20170152282A9 (en) 2017-06-01
KR101993899B1 (ko) 2019-09-24
AU2020202016C1 (en) 2022-03-24
JP2025024078A (ja) 2025-02-19
US9676812B2 (en) 2017-06-13
US20170190732A1 (en) 2017-07-06
IL278396B1 (en) 2024-03-01
CA2895513A1 (en) 2014-06-26
JP2021098739A (ja) 2021-07-01
CY1121150T1 (el) 2020-05-29
KR20190076072A (ko) 2019-07-01
CN109970833A (zh) 2019-07-05
JP2019182870A (ja) 2019-10-24
AU2020202016B2 (en) 2021-09-23
PH12018502141A1 (en) 2019-04-15
PT2935307T (pt) 2018-07-31
KR102400891B1 (ko) 2022-05-20
EP3392260B1 (en) 2022-09-21
US20150315230A1 (en) 2015-11-05
JP6542127B2 (ja) 2019-07-10
US10342809B2 (en) 2019-07-09
EP2935307A4 (en) 2016-08-03
AU2018217213A1 (en) 2018-08-30
SG11201504848QA (en) 2015-07-30
US20230190770A1 (en) 2023-06-22
WO2014100228A1 (en) 2014-06-26
SG10201706063UA (en) 2017-09-28
IL278396A (en) 2020-12-31
RU2663665C2 (ru) 2018-08-08
KR20150100771A (ko) 2015-09-02
CN105026415A (zh) 2015-11-04
NZ709211A (en) 2018-02-23
JP2016503793A (ja) 2016-02-08
AU2020202016A1 (en) 2020-04-09
EP2935307B1 (en) 2018-04-25
CN109970833B (zh) 2022-05-27
ES2680582T3 (es) 2018-09-10
EP2935307A1 (en) 2015-10-28
JP7589275B2 (ja) 2024-11-25
JP6852118B2 (ja) 2021-03-31
IL278396B2 (en) 2024-07-01
US20200113916A1 (en) 2020-04-16
EP3392260A1 (en) 2018-10-24
HK1216255A1 (en) 2016-10-28
CA2895513C (en) 2021-04-27
CN114605486A (zh) 2022-06-10

Similar Documents

Publication Publication Date Title
AU2021290223B2 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
HK1260534A1 (en) Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment
HK40086399A (en) Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment
HK1260534B (en) Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment
HK1216255B (en) Neuroactive 19-alkoxy-17-substituted steroids, useful in methods of treatment